AGA临床实践指南:肝细胞癌的系统治疗
美国胃肠病学会组建多学科小组,按GRADE框架评估晚期肝细胞癌系统治疗证据,针对不适合局部治疗或切除、转移性疾病且肝功能保留、肝功能差及辅助治疗患者形成11条推荐。
要点
- 指南涵盖一线贝伐珠单抗+阿替利珠单抗、索拉非尼、仑伐替尼及二线卡博替尼、帕博利珠单抗、雷莫西尤单抗、瑞戈非尼等药物。
- 推荐聚焦于不适合局部治疗或切除、转移性疾病且肝功能保留、肝功能差及辅助治疗人群。
- 采用GRADE框架评估证据,并通过证据到决策框架制定推荐。
核心结论
- 专家组就肝细胞癌系统治疗达成11条推荐,覆盖不适合局部治疗或切除、转移性疾病且肝功能保留、肝功能差及辅助治疗患者。
研究设计与样本
- 美国胃肠病学会组建由技术审查组和指南专家组组成的多学科小组制定本指南。
- 技术审查组按对临床医生和患者的重要性优先排序临床问题与结局,并对晚期肝细胞癌系统治疗进行证据审查。
- 采用推荐分级的评估、制定与评价(GRADE)框架评估证据,指南专家组使用证据到决策框架制定推荐。
主要发现
- 证据审查涵盖美国食品药品监督管理局批准用于肝细胞癌的药物:一线为贝伐珠单抗+阿替利珠单抗、索拉非尼和仑伐替尼。
- 二线药物包括卡博替尼、帕博利珠单抗、雷莫西尤单抗和瑞戈非尼。
- 其他药物包括贝伐珠单抗、纳武利尤单抗和纳武利尤单抗+伊匹木单抗。
关键数值与推荐
- 专家组就肝细胞癌系统治疗达成11条推荐。
临床怎么用
- 原文未据此给出具体推荐条款。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a deadly cancer, with an incidence that has tripled in the United States since 1980. In recent years, new systemic therapies for HCC have been approved and a critical assessment of the existing data is necessary to balance benefits and harms and inform the development of evidence-based guidelines. METHODS: The American Gastroenterological Association formed a multidisciplinary group consisting of a Technical Review Panel and a Guideline Panel. The Technical Review Panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conducted an evidence review of systemic therapies in patients with advanced-stage HCC. The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence. The Guideline Panel reviewed the evidence and used the Evidence-to-Decision Framework to develop recommendations. RESULTS: The Panel reviewed the evidence, summarized in the Technical Review, for the following medications approved by the US Food and Drug Administration for HCC: first-line therapies: bevacizumab+atezolizumab, sorafenib, and lenvatinib; second-line therapies: cabozantinib, pembrolizumab, ramucirumab, and regorafenib; and other agents: bevacizumab, nivolumab, and nivolumab+ipilimumab. CONCLUSIONS: The Panel agreed on 11 recommendations focused on systemic therapy for HCC in patients who are not eligible for locoregional therapy or resection, those with metastatic disease and preserved liver function, those with poor liver function, and those on systemic therapy as adjuvant therapy.
引用
- Su GL, Altayar O, O'Shea R, et al. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology. 2022. PMID: 35210014. doi:10.1053/j.gastro.2021.12.276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。